{"id":"aclacinomycin-cytarabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (aclacinomycin-related)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neurotoxicity (cytarabine-related)"}]},"_chembl":{"chemblId":"CHEMBL498884","moleculeType":"Small molecule","molecularWeight":"809.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aclacinomycin is an anthracycline antibiotic that intercalates into DNA and generates reactive oxygen species, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Together, they provide synergistic cytotoxic effects against leukemic cells through multiple mechanisms of DNA damage.","oneSentence":"This combination of aclacinomycin and cytarabine works by intercalating into DNA and inhibiting DNA synthesis to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:27.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT05662956","phase":"PHASE2","title":"A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients","status":"COMPLETED","sponsor":"Hematology department of the 920th hospital","startDate":"2022-12-01","conditions":"Acute Myeloid Leukemia","enrollment":114},{"nctId":"NCT05726110","phase":"PHASE3","title":"Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2023-01-29","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT05805072","phase":"NA","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-05-01","conditions":"Relapsed/Refractory AML","enrollment":20},{"nctId":"NCT05807347","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Hematology department of the 920th hospital","startDate":"2023-02-01","conditions":"Refractory/Relapse Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT03181815","phase":"PHASE2","title":"Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01-01","conditions":"Acute Myeloid Leukemia, Relapse Leukemia","enrollment":48},{"nctId":"NCT02662647","phase":"PHASE2","title":"Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-04","conditions":"AML","enrollment":30},{"nctId":"NCT03642236","phase":"PHASE2, PHASE3","title":"Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-08","conditions":"FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase","enrollment":122},{"nctId":"NCT02850822","phase":"","title":"Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-07","conditions":"Myelodysplastic Syndrome, Chemotherapy","enrollment":250},{"nctId":"NCT03026842","phase":"PHASE4","title":"Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-01","conditions":"Acute Myeloid Leukemia","enrollment":180},{"nctId":"NCT02432911","phase":"NA","title":"Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old","status":"UNKNOWN","sponsor":"Jianxiang Wang","startDate":"2015-04","conditions":"Acute Myeloid Leukemia","enrollment":300},{"nctId":"NCT02432872","phase":"NA","title":"Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years","status":"UNKNOWN","sponsor":"Jianxiang Wang","startDate":"2015-04","conditions":"Acute Myeloid Leukemia","enrollment":300},{"nctId":"NCT01690507","phase":"PHASE1, PHASE2","title":"Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2012-11","conditions":"MDS, AML","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aclacinomycin, Cytarabine","genericName":"Aclacinomycin, Cytarabine","companyName":"The First Hospital of Jilin University","companyId":"the-first-hospital-of-jilin-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of aclacinomycin and cytarabine works by intercalating into DNA and inhibiting DNA synthesis to kill rapidly dividing cancer cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}